Go Pro
→ WATCH THIS BEFORE DECEMBER 8th!! (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$41.40
+2.3%		$42.92
$14.25
▼
$48.51
$4.50B0.351.64 million shs1.43 million shs
MannKind Corporation stock logo
MNKD
MannKind
$3.80
-3.8%		$3.86
$2.23
▼
$6.51
$1.22B1.095.06 million shs4.61 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$23.24
-4.9%		$24.85
$6.69
▼
$34.39
$3.92B1.173.04 million shs5.25 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$29.94
-1.9%		$33.35
$25.77
▼
$43.15
$3.77B0.667.82 million shs6.34 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+5.24%-1.31%+4.65%+168.13%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+13.77%-4.04%-15.93%-29.37%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
0.00%-6.74%+2.11%-21.11%+191.59%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%-15.80%-11.89%-20.03%+9.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$41.40
+2.3%		$42.92
$14.25
▼
$48.51
$4.50B0.351.64 million shs1.43 million shs
MannKind Corporation stock logo
MNKD
MannKind
$3.80
-3.8%		$3.86
$2.23
▼
$6.51
$1.22B1.095.06 million shs4.61 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$23.24
-4.9%		$24.85
$6.69
▼
$34.39
$3.92B1.173.04 million shs5.25 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$29.94
-1.9%		$33.35
$25.77
▼
$43.15
$3.77B0.667.82 million shs6.34 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+5.24%-1.31%+4.65%+168.13%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+13.77%-4.04%-15.93%-29.37%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
0.00%-6.74%+2.11%-21.11%+191.59%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%-15.80%-11.89%-20.03%+9.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.82
Moderate Buy$51.3323.99% Upside
MannKind Corporation stock logo
MNKD
MannKind
2.50
Moderate Buy$8.34119.57% Upside
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2.75
Moderate Buy$43.4687.01% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.75
Moderate Buy$99.67232.89% Upside

Current Analyst Ratings Breakdown

Latest MNKD, EWTX, TNGX, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$83.00 ➝ $87.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$120.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $57.00
9/11/2026
MannKind Corporation stock logo
MNKD
MannKind
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$8.00
9/3/2026
MannKind Corporation stock logo
MNKD
MannKind
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/20/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$53.00 ➝ $60.00
8/18/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$66.00 ➝ $68.00
8/18/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/12/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $35.00
(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.93 per shareN/A
MannKind Corporation stock logo
MNKD
MannKind
$348.97M3.50$0.06 per share61.41($0.17) per share-22.35
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$62.38M62.82N/AN/A$2.57 per share9.04
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.85N/AN/AN/AN/A-39.01%-36.96%11/5/2026 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.13N/AN/AN/A-11.08%N/A-6.31%11/4/2026 (Estimated)
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.59M-$0.85N/AN/AN/AN/A-25.75%-23.36%11/3/2026 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.66N/AN/AN/AN/A-94.56%-82.75%10/28/2026 (Estimated)

Latest MNKD, EWTX, TNGX, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.07N/AN/AN/AN/AN/A
8/11/2026Q2 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.3172-$0.37-$0.0528-$0.37$1.56 millionN/A
8/6/2026Q2 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.4677-$0.53-$0.0623-$0.53N/AN/A
8/5/2026Q2 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.0075-$0.01-$0.0025-$0.06$108.08 million$109.37 million
7/29/2026Q2 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.21-$1.10+$0.11-$1.10N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
16.24
16.24
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.72
1.41
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
50.82
50.82
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
4.72
4.72

Institutional Ownership

CompanyInstitutional Ownership
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
MannKind Corporation stock logo
MNKD
MannKind
2.60%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.50%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
127108.60 million85.47 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
592321.54 million313.18 millionOptionable
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
137168.61 million157.65 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
65125.99 million119.31 millionOptionable

Recent News About These Companies

Viking Therapeutics (NASDAQ:VKTX) Stock Rating Cut to "Strong Sell" at Wall Street Zen
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083592
Wall Street Zen Downgrades Viking Therapeutics (NASDAQ:VKTX) to Strong Sell
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-downgrades-viking-therapeutics-nasdaq-vktx-to-strong-sell-2026-10-04/
Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy?
October 2 at 11:14 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-viking-therapeutics-vktx-pairing-140918447.html
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
October 2 at 10:16 AM  |  zacks.comhttps://www.zacks.com/stock/news/2999377/lly-highlights-new-efficacy-data-from-foundayo-and-eloratzp-studies?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2999377
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
October 1 at 6:46 PM  |  zacks.comhttps://www.zacks.com/stock/news/2999182/viking-therapeutics-inc-vktx-stock-declines-while-market-improves-some-information-for-investors?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6-2999182
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
October 1 at 6:01 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-inc-vktx-stock-204508910.html
Laboratory workstation with a centrifuge, pipettes, sample racks, and automated liquid-handling equipment on a metal bench.
3 Emerging Biotech Stocks With Significant Upside Potential (VKTX)
...
October 1 at 7:25 AM  |  marketbeat.comhttps://www.marketbeat.com/articles/3-emerging-biotech-stocks-with-significant-upside-potential/
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998508/viking-therapeutics-inc-vktx-rises-as-market-takes-a-dip-key-facts?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2998508
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-inc-vktx-rises-205006106.html
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
September 30, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/30/viking-therapeutics-stock-soars-20-on-weight-loss/
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
September 29, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/29/eli-lilly-stock-barely-moved-following-viking-ther/
3 Non-AI Growth Stocks That Have Massive Upside
September 29, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/29/3-non-ai-growth-stocks-that-have-massive-upside/
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
September 29, 2026  |  stocktwits.comS
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase ...
September 28, 2026  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=600-202609281630PR_NEWS_USPRX____LA58434-1
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-closing-concurrent-203000029.html
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
September 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/viking-therapeutics-announces-closing-of-concurrent-upsized-offerings-of-common-stock-and-convertible-senior-notes-including-full-exercise-of-underwriters-options-to-purchase-additional-shares-of-common-stock-and-convertible-sen-302891919.html
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-viking-123002734.html
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver
September 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950302-viking-therapeutics-adds-weight-loss-maintenance-potential-new-growth-driver
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
September 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-viking-therapeutics-inc-to-contact-law-firm-302891041.html
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
September 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2996571/wall-street-analysts-think-viking-therapeutics-vktx-is-a-good-investment-is-it?cid=cs-stocknewsapi-ft-fundamental_analysis|average_broker_rating-2996571
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
September 27, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/27/viking-therapeutics-delivers-great-vk2735-results/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Viking Therapeutics logo displayed among laboratory glassware, a vial, and a syringe in a lab setting.
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
By Chris Markoch | September 23, 2026
Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$41.40 +0.92 (+2.27%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$41.40 0.00 (0.00%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.80 -0.15 (-3.80%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$3.80 0.00 (0.00%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$23.24 -1.21 (-4.95%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$22.92 -0.31 (-1.36%)
As of 10/2/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$29.94 -0.57 (-1.87%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$30.02 +0.07 (+0.25%)
As of 10/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas